Anti-neutrophil antibodies are capable of activating neutrophils in sterile environments, releasing extracellular traps containing myeloperoxidase (MPO) and anti-MPO antibodies (MPO-ANCAs or anti-MPO-ANCAs), which have been implicated in the pathogenesis of several diseases. The present study evaluated systemic and tumor tissue levels of anti-MPO-ANCAs breast cancer patients, and its relation to clinicopathological characteristics. Anti-MPO-ANCAs were measured in serum and tissue samples of 150 patients by enzyme-linked immunoassay. Samples were pooled according to clinicopathological characteristics of patients. Higher anti-MPO-ANCAs levels were detected in groups presenting negative clinicopathological characteristics, such as high histological grade tumors and risk factors such as body mass index, menopausal status and early onset at diagnosis. The present data highlights anti-MPO-ANCAs as associated to poor prognosis in breast cancer, a role beyond its actually discussed role in autoimmunity and vasculitis.

抗中性粒细胞抗体能够在无菌环境中激活中性粒细胞，释放含有髓过氧化物酶 (MPO) 和抗 MPO 抗体（MPO-ANCAs 或抗 MPO-ANCAs）的细胞外陷阱，这些抗体与多种疾病的发病机制有关。本研究评估了抗 MPO-ANCAs 乳腺癌患者的全身和肿瘤组织水平，及其与临床病理特征的关系。通过酶联免疫测定法测量了 150 名患者的血清和组织样本中的抗 MPO-ANCA。根据患者的临床病理特征合并样本。在呈现阴性临床病理特征的组中检测到较高的抗 MPO-ANCAs 水平，例如高组织学分级肿瘤和危险因素，例如体重指数、更年期状态和诊断早期发病。